teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 11 Projects Releases Packages Wiki Activity Actions 1

extract: 2024-11-01-aspe-medicare-anti-obesity-medication-coverage

Browse source 
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
This commit is contained in:
Teleo Agents 2026-03-16 11:27:11 +00:00
parent 4576cbbe76
commit e4ddbac207
2 changed files with 20 additions and 1 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

6
domains/health/federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings.md
View file

@ -39,6 +39,12 @@ The GLP-1 case is particularly stark because the clinical evidence is robust (ca
The claim that budget scoring "systematically" undervalues prevention requires evidence beyond a single case. However, the GLP-1 divergence is consistent with known CBO methodology (10-year window, conservative assumptions) and parallels similar scoring challenges for other preventive interventions (vaccines, screening programs). The structural bias is well-documented in health policy literature, though this source provides the most dramatic single-case illustration. The claim that budget scoring "systematically" undervalues prevention requires evidence beyond a single case. However, the GLP-1 divergence is consistent with known CBO methodology (10-year window, conservative assumptions) and parallels similar scoring challenges for other preventive interventions (vaccines, screening programs). The structural bias is well-documented in health policy literature, though this source provides the most dramatic single-case illustration.
### Additional Evidence (confirm)
*Source: [[2024-11-01-aspe-medicare-anti-obesity-medication-coverage]] | Added: 2026-03-16*
The CBO vs. ASPE divergence on Medicare GLP-1 coverage provides concrete evidence: CBO projects $35B in additional spending (2026-2034) using budget scoring methodology, while ASPE projects net savings of $715M over 10 years using clinical economics methodology that includes downstream event avoidance. The $35.7B gap between these estimates demonstrates how budget scoring rules structurally disadvantage preventive interventions. CBO uses conservative uptake assumptions and doesn't fully count avoided hospitalizations and disease progression within the 10-year window, while ASPE includes 38,950 CV events avoided and 6,180 deaths avoided. Both are technically correct but answer different questions—budget impact vs. clinical economics.
--- ---
Relevant Notes: Relevant Notes:

15
inbox/archive/2024-11-01-aspe-medicare-anti-obesity-medication-coverage.md
View file

@ -7,9 +7,13 @@ date: 2024-11-01
domain: health domain: health
secondary_domains: [internet-finance] secondary_domains: [internet-finance]
format: policy format: policy
status: unprocessed status: enrichment
priority: medium priority: medium
tags: [glp-1, medicare, obesity, budget-impact, CBO, federal-spending] tags: [glp-1, medicare, obesity, budget-impact, CBO, federal-spending]
processed_by: vida
processed_date: 2026-03-16
enrichments_applied: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings.md"]
extraction_model: "anthropic/claude-sonnet-4.5"
--- ---
## Content ## Content
@ -45,3 +49,12 @@ WHY ARCHIVED: The CBO vs. ASPE divergence reveals a systematic bias in how preve
EXTRACTION HINT: Focus on the methodological divergence as evidence of structural misalignment in policy evaluation, not just the GLP-1 budget numbers EXTRACTION HINT: Focus on the methodological divergence as evidence of structural misalignment in policy evaluation, not just the GLP-1 budget numbers
flagged_for_leo: ["Budget scoring methodology systematically disadvantages prevention — this is a cross-domain structural problem affecting all preventive health investments"] flagged_for_leo: ["Budget scoring methodology systematically disadvantages prevention — this is a cross-domain structural problem affecting all preventive health investments"]
## Key Facts
- CBO estimates Medicare coverage of anti-obesity medications would increase federal spending by $35 billion over 2026-2034
- ASPE estimates net savings of $715 million over 10 years from Medicare GLP-1 coverage (range: $412M to $1.04B)
- Broad semaglutide access projected to avoid 38,950 CV events and 6,180 deaths over 10 years
- Annual Part D cost increase from Medicare GLP-1 coverage: $3.1-6.1 billion
- Approximately 10% of Medicare beneficiaries would be eligible under proposed criteria requiring comorbidities
- Proposed eligibility criteria require CVD history, heart failure, CKD, or prediabetes—not just BMI threshold